VGLL2-NCOA2 leverages developmental programs for pediatric sarcomagenesis
S. Watson, C. LaVigne, L. Xu, W. Murchison, D. Surdez, D. Rakheja, F. Tirode, O. Delattre, J. Amatruda, G. C. Kendall
This study identifies VGLL2-NCOA2 as an oncogene driving pediatric sarcomagenesis by reactivating developmental programs, with ARF6 overexpression as a potential therapeutic target.
bioRxiv · Sep 15, 2021Cancer Biology